Table 4.
Hepatitis B and C cohorts.
| Cancer | Viral hepatitis | Immunotherapy | Anti-viral therapy | Viral load (IU/ml) | Response | IrAE |
|---|---|---|---|---|---|---|
| Melanoma | Hepatitis B | Sequential pembrolizumab + ipilimumab | Nil | <20-> 20-> <20-> <20 |
SD | – |
| Melanoma | Hepatitis B | Pembrolizumab | Tenofovir | <20-> 20-> <20-> <20 |
SD | – |
| Melanoma | Hepatitis B | Pembrolizumab | Tenofovir | Unknown | PR | G2 hypothyroidism |
| Melanoma | Hepatitis B | Pembrolizumab | Entecavir | Unknown | PD | – |
| Melanoma | Hepatitis B | Pembrolizumab | Nil | Unknown | PD | – |
| Melanoma | Hepatitis B | Pembrolizumab | Nil | <20-> <20-> <20-> <20 |
CR | G1 rash |
| Melanoma | Hepatitis B | Pembrolizumab | Nil | Unknown | PD | G2 rash |
| Melanoma | Hepatitis B | Nivolumab | Entecavir | 279-> 20-> <20-> 43 |
SD | G2 pneumonitis |
| Melanoma | Hepatitis B | Nivolumab | Nil | 300-> 170 | PR | G1 vitiligo |
| Mesothelioma | Hepatitis B | Pembrolizumab | Entecavir | 467-> <20-> <20-> <20 |
SD | – |
| Hepatocellular carcinoma | Hepatitis B | Nivolumab | Tenofovir | 39-> <20-> <20-> <20 |
SD | – |
| Glioblastoma | Hepatitis B | Pembrolizumab | Entecavir | <20-> 20-> <20-> <20 |
SD | – |
| Gastric carcinoma | Hepatitis B | Pembrolizumab | Nil | Unknown | SD | – |
| Urothelial carcinoma | Hepatitis B | Nivolumab | Entecavir | Unknown | SD | – |
| Melanoma | Hepatitis C | Concurrent nivolumab + ipilimumab | Sofosbuvir and ribavirin | 6,550,000- > undetectable |
CR | G4 colitis |
| Melanoma | Hepatitis C | Concurrent nivolumab + ipilimumab | Ledipasvir and sofosbuvir | 9,360,000 | PR | G3 autoimmune hepatitis |
| Melanoma | Hepatitis C | Sequential nivolumab + ipilimumab | Ombitasvir, paritaprevir, ritonavir and dasabuvir | 1,218,319-> 920,912 |
PD | – |
| Melanoma | Hepatitis C | Sequential pembrolizumab + ipilimumab | Interferon | 58,000 | CR | – |
| Melanoma | Hepatitis C | Pembrolizumab | Nil | Unknown | SD | G3 adrenal insufficiency |
| Melanoma | Hepatitis C | Pembrolizumab | Nil | Unknown | SD | – |
| Melanoma | Hepatitis C | Pembrolizumab | Ribavirin and pegylated interferon | Undetectable | PD | – |
| Melanoma | Hepatitis C | Nivolumab | Nil | Undetectable | SD | – |
| Melanoma | Hepatitis C | Nivolumab | Nil | Unknown | SD | – |
| Urothelial carcinoma | Hepatitis C | Nivolumab | Ribavirin and pegylated interferon | 81,159 | SD | G1 rash |
| Urothelial carcinoma | Hepatitis C | Atezolizumab | Ledipasvir and sofosbuvir | Undetectable | SD | – |
| Mesothelioma | Hepatitis C | Pembrolizumab | Unknown | 903,029 | SD | – |
| Renal cell carcinoma | Hepatitis C | Nivolumab | Ledipasvir and sofosbuvir | 379,836- > Undetectable |
SD | – |
| Non-small cell lung cancer | Hepatitis C | Nivolumab | Ledipasvir and sofosbuvir | 3,952,419- > undetectable |
SD | – |
CR: complete response; PR: partial response; SD: stable disease; PD: disease progression; irAE: immune-related adverse event.